Harvard Bioscience, Inc. (HBIO)
| Market Cap | 36.19M +69.9% |
| Revenue (ttm) | 87.81M -1.1% |
| Net Income | -10.41M |
| EPS | -2.35 |
| Shares Out | 4.55M |
| PE Ratio | n/a |
| Forward PE | 44.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,095 |
| Open | 7.94 |
| Previous Close | 7.95 |
| Day's Range | 7.91 - 8.04 |
| 52-Week Range | 3.76 - 9.40 |
| Beta | 1.53 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About HBIO
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including d... [Read more]
Financial Performance
In 2025, Harvard Bioscience's revenue was $86.55 million, a decrease of -8.06% compared to the previous year's $94.14 million. Losses were -$56.70 million, 357.1% more than in 2024.
Financial StatementsNews
Harvard Bioscience price target raised to $7.50 from $6 at Benchmark
Benchmark raised the firm’s price target on Harvard Bioscience (HBIO) to $7.50 from $6 and keeps a Speculative Buy rating on the shares. The increased profitability and cash flow from…
Harvard Bioscience Earnings Call Transcript: Q2 2026
Q2 revenue grew 11% year-over-year to $22.7 million, driven by strong demand in CMT, preclinical, and APAC markets. Recurring revenue rose to 55%, and full-year guidance was raised for revenue and adjusted EBITDA. Project Viking and localization initiatives are on track for future cost savings.
Harvard Bioscience Earnings release: Q2 2026
Harvard Bioscience released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Harvard Bioscience Slides: Q2 2026
Harvard Bioscience has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 11, 2026.
Harvard Bioscience Quarterly report: Q2 2026
Harvard Bioscience has published its Q2 2026 quarterly earnings report on August 11, 2026.
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET
HOLLISTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2026, before the market opens on August 1...
Harvard Bioscience management to meet with KeyBanc
Meeting to be held in New York on June 24-25 hosted by KeyBanc.
Harvard Bioscience Transcript: AGM 2026
The meeting confirmed a quorum and addressed five key proposals, including director elections, auditor ratification, executive compensation, and amendments to stock plans. All proposals received board support and were approved by shareholder vote.
Harvard Bioscience Transcript: Sidoti Micro-Cap Virtual Conference
Leadership and board have been refreshed, with a strategic focus on translational science and operational consolidation. Financial guidance targets improved margins and recurring revenue, driven by new product innovation and expanding pharma/biotech sales. Project Viking and debt restructuring are expected to yield significant cost savings and support future growth.
Harvard Bioscience reports Q1 adjusted EPS (33c) vs. ($1.25) last year
Reports Q1 revenue $20.8M vs. $21.8M last year. The company noted encouraging adoption rates within its NPI portfolio, specifically the MeshMEA organoid platform and BTX Electroporation systems, which...
Harvard Bioscience reiterates Q2 revenue view $20.5M-$22.5M
Sees Q2 adjusted gross margin between 57%-59%. Sees Q2 adjusted EBITDA between $1M-$2M. Expects year-over-year revenue growth in the mid-single digit range at the midpoint of guidance. Published first...
Harvard Bioscience reaffirms FY26 revenue growth of 2%-4%
Reaffirms FY26 adjusted gross margin outlook between 58%060% and adjusted EBITDA growth between 6%-10%.
Harvard Bioscience Earnings Call Transcript: Q1 2026
Q1 2026 revenue was $20.8M with a 59% adjusted gross margin, driven by new product growth and higher pharma/biotech sales. Guidance for 2026 is reaffirmed, with expected revenue growth of 2%-4% and margin expansion, while Project Viking and new initiatives support long-term profitability.
Harvard Bioscience Earnings release: Q1 2026
Harvard Bioscience released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Harvard Bioscience Slides: Q1 2026
Harvard Bioscience has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
Harvard Bioscience Quarterly report: Q1 2026
Harvard Bioscience has published its Q1 2026 quarterly earnings report on May 12, 2026.
Harvard Bioscience Announces First Quarter 2026 Financial Results
First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 20...
Harvard Bioscience Slides: Investor presentation
Harvard Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Harvard Bioscience to Participate in Upcoming Investor Conferences
HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost's participation in...
Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12...
Harvard Bioscience Proxy statement: Proxy filing
Harvard Bioscience filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Harvard Bioscience Proxy statement: Proxy filing
Harvard Bioscience filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Harvard Bioscience Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Leadership is focused on innovation and operational efficiency, targeting high-growth areas like organoids and bioproduction. Financials are strong with improved margins, reduced debt service, and new products expected to double their revenue share. Academic, pharma, and CRO markets are key segments, with Asia showing recovery.
Harvard Bioscience Slides: FY 2026
Harvard Bioscience has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 17, 2026.
Harvard Bioscience price target adjusted to $6 at Benchmark after reverse split
Benchmark analyst Bruce Jackson raised the firm’s price target on Harvard Bioscience (HBIO) to $6 from 60c and keeps a Speculative Buy rating on the shares after updating the firm’s…